Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Cash from Operations (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Cash from Operations for 5 consecutive years, with 15156000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations fell 21.62% to 15156000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 63520000.0, a 36.54% decrease, with the full-year FY2024 number at 56188000.0, down 72.29% from a year prior.
  • Cash from Operations was 15156000.0 for Q3 2025 at Werewolf Therapeutics, roughly flat from 15164000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 303000.0 in Q2 2022 to a low of 18948000.0 in Q1 2025.
  • A 5-year average of 11660000.0 and a median of 12462000.0 in 2024 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: soared 97.1% in 2022, then tumbled 3504.29% in 2023.
  • Werewolf Therapeutics' Cash from Operations stood at 12673000.0 in 2021, then increased by 6.34% to 11870000.0 in 2022, then soared by 61.37% to 4585000.0 in 2023, then plummeted by 210.84% to 14252000.0 in 2024, then decreased by 6.34% to 15156000.0 in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Cash from Operations are 15156000.0 (Q3 2025), 15164000.0 (Q2 2025), and 18948000.0 (Q1 2025).